KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 151–167 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12D3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2251 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2252 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 16497971 · Hoang et al., 2006 · Open in CIViC	civic
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID937 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic
KRAS G12C4
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2261 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2262 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS G12S3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2277 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2278 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS RS617643701
Carboplatin + PaclitaxelSubstitutes	Ovarian CarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID664 The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC) PMID 22139083 · Ratner et al., 2012 · Open in CIViC	civic
KRAS G12/G132
Gemcitabine + TrametinibCombination	Pancreatic Adenocarcinoma	Predictive	B	Supports Resistance	4	accepted	EID622 Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastati… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
Trametinib	Pancreatic Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID990 KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
KRAS Mutation1
PI3Kbeta Inhibitor AZD8186 + SCH772984Combination	Pancreatic Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1003 Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC) PMID 26725216 · Hayes et al., 2016 · Open in CIViC	civic
KRAS Exon 2 Mutation1
Erlotinib	Pancreatic Carcinoma	Predictive	B	Does Not Support Resistance	3	accepted	EID916 KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment. PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7492 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7493 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Mar 8, 2011	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Mar 8, 2011	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	Mar 8, 2011	openfda

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 101–150 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05172245	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer	recruiting	Phase 1	46	National Cancer Institute (NCI)NIH	2	Sep 22, 2026	clinicaltrials
NCT05215548	Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	recruiting	Phase 2	100	National Taiwan University HospitalOTHER	1	Sep 22, 2026	clinicaltrials
NCT05276973	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	active not recruiting	Phase 1	25	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06066138	A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06109272	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2)	active not recruiting	Phase 2 / Phase 3	89	AbbVieINDUSTRY	6	Sep 22, 2026	clinicaltrials
NCT06140836	A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)	active not recruiting	Phase 3	190	Bristol-Myers SquibbINDUSTRY	21	Sep 22, 2026	clinicaltrials
NCT06445062	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	recruiting	Phase 1 / Phase 2	1,130	Revolution Medicines, Inc.INDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT06712316	Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	recruiting	Phase 2 / Phase 3	1,580	BioNTech SEINDUSTRY	22	Sep 22, 2026	clinicaltrials
NCT06875310	A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)	recruiting	Phase 3	630	Mirati Therapeutics Inc.INDUSTRY	35	Sep 22, 2026	clinicaltrials
NCT07059845	A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer(FLORENZA)	recruiting	Phase 2	400	AbbVieINDUSTRY	8	Sep 22, 2026	clinicaltrials
NCT07100080	Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)	recruiting	Phase 2 / Phase 3	500	Bristol-Myers SquibbINDUSTRY	25	Sep 22, 2026	clinicaltrials
NCT07409272	A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer	recruiting	Phase 3	614	Astellas Pharma Global Development, Inc.INDUSTRY	6	Sep 22, 2026	clinicaltrials
NCT07415031	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies	recruiting	Phase 2	170	Mirati Therapeutics Inc.INDUSTRY	20	Sep 22, 2026	clinicaltrials
NCT07619521	Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma	recruiting	Phase 1 / Phase 2	31	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT07769502	A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers	recruiting	Phase 2	168	AbbVieINDUSTRY	3	Sep 22, 2026	clinicaltrials
NCT07816380	A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer	not yet recruiting	Phase 3	216	Guangzhou JOYO Pharma Co., LtdINDUSTRY	0	Sep 22, 2026	clinicaltrials
NCT07833735	A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors	not yet recruiting	Phase 1 / Phase 2	400	CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY	0	Sep 22, 2026	clinicaltrials
NCT04216316	Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer	active not recruiting	Phase 1 / Phase 2	12	National Cancer Institute (NCI)NIH	1	Sep 21, 2026	clinicaltrials
NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma(LIMIT)	active not recruiting	Phase 1 / Phase 2	41	Ravi Amaravadi, MDOTHER	1	Sep 21, 2026	clinicaltrials
NCT04543071	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma	active not recruiting	Phase 2	118	Columbia UniversityOTHER	1	Sep 21, 2026	clinicaltrials
NCT04644068	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA)	active not recruiting	Phase 1 / Phase 2	702	AstraZenecaINDUSTRY	14	Sep 21, 2026	clinicaltrials
NCT06040099	A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE(EMERALD-Y90)	active not recruiting	Phase 2	58	AstraZenecaINDUSTRY	1	Sep 21, 2026	clinicaltrials
NCT06745882	Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC	recruiting	Phase 2	318	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 21, 2026	clinicaltrials
NCT07111546	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]	recruiting	Phase 2	140	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Sep 21, 2026	clinicaltrials
NCT07495124	IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence	recruiting	Phase 2	26	University of WashingtonOTHER	1	Sep 21, 2026	clinicaltrials
NCT07829926	Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC)	not yet recruiting	Phase 2	120	First Affiliated Hospital of Wenzhou Medical UniversityOTHER	0	Sep 21, 2026	clinicaltrials
NCT07831902	Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer(NSMP-ORANGE)	recruiting	Phase 3	600	University College, LondonOTHER	1	Sep 21, 2026	clinicaltrials
NCT07832227	Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA)	not yet recruiting	Phase 2	60	Dana-Farber Cancer InstituteOTHER	0	Sep 21, 2026	clinicaltrials
NCT03391869	Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	active not recruiting	Phase 3	339	M.D. Anderson Cancer CenterOTHER	1	Sep 18, 2026	clinicaltrials
NCT04439253	Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)	active not recruiting	Phase 2	4	National Cancer Institute (NCI)NIH	1	Sep 18, 2026	clinicaltrials
NCT04752826	BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)	recruiting	Phase 1 / Phase 2	250	BioInvent International ABINDUSTRY	7	Sep 18, 2026	clinicaltrials
NCT05267626	Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	recruiting	Phase 1 / Phase 2	159	Aulos Bioscience, Inc.INDUSTRY	2	Sep 18, 2026	clinicaltrials
NCT06692738	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	recruiting	Phase 3	1,160	AstraZenecaINDUSTRY	26	Sep 18, 2026	clinicaltrials
NCT06859762	A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors	recruiting	Phase 1	630	MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY	2	Sep 18, 2026	clinicaltrials
NCT07827872	Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma	not yet recruiting	Phase 3	300	caohaotianOTHER	1	Sep 18, 2026	clinicaltrials
NCT07828756	Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer	not yet recruiting	Phase 2	147	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Sep 18, 2026	clinicaltrials
NCT06287775	Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	recruiting	Phase 1 / Phase 2	45	National Cancer Institute (NCI)NIH	1	Sep 17, 2026	clinicaltrials
NCT06340568	A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01)	recruiting	Phase 3	480	BioNTech SEINDUSTRY	26	Sep 17, 2026	clinicaltrials
NCT06952504	A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033)	recruiting	Phase 3	1,123	Merck Sharp & Dohme LLCINDUSTRY	34	Sep 17, 2026	clinicaltrials
NCT07195695	Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations	recruiting	Phase 3	400	Boehringer IngelheimINDUSTRY	28	Sep 17, 2026	clinicaltrials
NCT07318558	A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)(TroFuse-021)	recruiting	Phase 3	900	Merck Sharp & Dohme LLCINDUSTRY	29	Sep 17, 2026	clinicaltrials
NCT07349537	Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors	recruiting	Phase 1	574	Revolution Medicines, Inc.INDUSTRY	1	Sep 17, 2026	clinicaltrials
NCT07566052	A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation	recruiting	Phase 3	356	Astellas Pharma Global Development, Inc.INDUSTRY	3	Sep 17, 2026	clinicaltrials
NCT07572864	Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC	recruiting	Phase 2	9	West China HospitalOTHER	1	Sep 17, 2026	clinicaltrials
NCT07576725	Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial	not yet recruiting	Phase 2	50	Fred Hutchinson Cancer CenterOTHER	1	Sep 17, 2026	clinicaltrials
NCT04273061	Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8)	recruiting	Phase 2	50	British Columbia Cancer AgencyOTHER	1	Sep 16, 2026	clinicaltrials
NCT04322383	Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	recruiting	Phase 2	40	National Cancer Institute (NCI)NIH	1	Sep 16, 2026	clinicaltrials
NCT04613596	Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7	recruiting	Phase 2 / Phase 3	626	Mirati Therapeutics Inc.INDUSTRY	47	Sep 16, 2026	clinicaltrials
NCT04741997	Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma	recruiting	Early Phase 1	50	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 16, 2026	clinicaltrials
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Sep 16, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)